Methods for treating il-6 mediated inflammation without immunosuppression

Abstract

The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.

What is claimed is: 
     
         1 . A method of treating a patient who has KDOQI stage 3-5 chronic kidney disease (CKD) with inflammation to reduce the risk of cardiovascular morbidity and mortality, comprising:
 administering a dose of 5-30 mg COR-001 subcutaneously once monthly to a patient with KDOQI stage 3-5 CKD and a CRP level greater than 2 mg/L,   wherein the dose is sufficient to reduce the CRP level to 2 mg/L or less and does not cause a decrease in absolute neutrophil count (ANC) below 1,500 cells/μL.   
     
     
         2 . The method of  claim 1 , wherein the method comprises administering 5-10 mg COR-001 subcutaneously once monthly to the patient. 
     
     
         3 . The method of  claim 1 , wherein the method comprises administering 10-20 mg COR-001 subcutaneously once monthly to the patient. 
     
     
         4 . The method of  claim 1 , wherein the method comprises administering 20-30 mg COR-001 subcutaneously once monthly to the patient. 
     
     
         5 . The method of  claim 1 , wherein the method comprises administering 15 mg COR-001 subcutaneously once monthly to the patient. 
     
     
         6 . The method of  claim 1 , wherein the method comprises administering 30 mg COR-001 subcutaneously once monthly to the patient. 
     
     
         7 . The method of  claim 1 , wherein post-treatment low-density lipoprotein (LDL) level is increased by no more than 10% as compared to pre-treatment levels. 
     
     
         8 . The method of  claim 1 , wherein the administration reduces the risk of heart failure and/or cardiovascular death. 
     
     
         9 . The method of  claim 1 , wherein the administration increases cardiac function. 
     
     
         10 . The method of  claim 1 , wherein the administration reduces fibrosis after acute myocardial infarction. 
     
     
         11 . The method according to  claim 1 , wherein the cardiovascular morbidity and mortality is selected from a group consisting of (i) nonfatal myocardial infarction, (ii) nonfatal stroke, and (iii) cardiovascular death. 
     
     
         12 . The method according to  claim 1 , wherein the cardiovascular morbidity and mortality is heart failure.